Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_assertion type Assertion NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_head.
- NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_assertion wasGeneratedBy ECO_0000203 NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_provenance.
- NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_assertion wasDerivedFrom befree-20140225 NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_provenance.
- NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_assertion SIO_000772 22169598 NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_provenance.
- NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_assertion evidence source_evidence_literature NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_provenance.
- NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_assertion description "[Further, we characterized the direct in vitro effects of the TLR9 agonist, CpG oligodeoxynucleotide (ODN), commonly used as a vaccine adjuvant in cancer immunotherapy, on glioma cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP215927.RAtYhUl0JJu8TgOWL_mNjocdN1iyShe8QUbWbfSeBGKAM130_provenance.